Sushil

First Hybrid brachytherapy with Aarhus applicator in chicoutimi hospital, Quebec @AmericanBrachy on brachy awareness day @KamravaMD @DocGlaser @AndrewKellerMD

✨ JUST OUT in EUO, New paper challenging a dogma. ⏩ MUST READ: @ConstanceHuck has done a great job to show that CIS is not always a contra-indication for Trimodal Therapy in the management of MIBC. 🙏Thanks to all co-authors for their input! sciencedirect.com/science/articl…

TDABC - important concept but not routinely calculated in health care. What is not measured can’t be improved @AndrewKellerMD

Congratulations Dr Morton for well deserved highest #ABS25 award for his contribution to the field of prostate brachy @KamravaMD @DrAndrewLoblaw @AndrewKellerMD @Sunnybrook

Fun interactive case based session on hybrid cervical brachytherapy #abs25 @AndrewFarach @NeilTaunkMD Yasmin Hassan @AndrewKellerMD @PranshuMohindra @KamravaMD

Practical guide for selection of hybrid applicator for cervical cancer @AmericanBrachy @KamravaMD @AndrewKellerMD @AndrewFarach medicalaffairs.varian.com/image/Selectio…

Multi institution largest series for definitive chemo RT for cancel of vulva lead by Anupam Rishi from Moffet ⁦@DocGlaser⁩ ⁦@KamravaMD⁩ ⁦@emmacfields⁩ ⁦@AnnKloppMD⁩ ⁦@ARRO_org⁩ pubmed.ncbi.nlm.nih.gov/40513383/

More to learn from molecular based treatment for endometrial cancer @KamravaMD

Our Study showing safety and improvement in lymphedema with intense resistance/strength training

Great work with 1st author @P_Shams_ and led by @AHNtoday radonc @ColinChampMD in @JAMANetworkOpen : Resistance Training and Lymphedema in Breast Cancer Survivors | Nutrition, Obesity, Exercise | JAMA Network Open | JAMA Network #bcsm @Sushilberiwal @DavidBartlettMD

With recent NEJM publications, increased interest in exercise in oncology . ⁦@ColinChampMD⁩ leading one of its kind structured program in this sphere ⁦@AHNtoday⁩ #bcsm ⁦@CShahMD⁩ jamanetwork.com/journals/jaman…

Adaptive brachy - why and how ? Winship Grand Rounds: April 23, 2025 - Sushil Beriwal, MD youtu.be/WH0CZ0IBne8?si… via @YouTube @AmericanBrachy @KamravaMD @AndrewKellerMD @ARRO_org @emmacfields @DocGlaser @reshmajagsi @jillremick

Finally one positive data on breast cancer for oligoprogression. Focused only on HR positive breast cancer unlike previous studies with goal to continue same systemic treatment #bcsm

This study reports on incredible results with adjuvant cemiplimab in high-risk cutaneous squamous cell carcinoma. nejm.org/doi/full/10.10…

NACRT better than NACT for resection and survival for locally advanced GB cancer. Nice work @TataMemorial

‼️ TAUTEM Phase 3 RCT T2-3bN0M0 rectal cancer -> chemoradiation and transanal excision vs TME DFS in both groups was 88.9%! Win for organ preservation and patients! jamanetwork.com/journals/jamas…

Final Update CATNON ASCO 2025 · Median F/U 11 yrs · NO sig benefit concurrent TMZ · Sig benefit (HR 0.54) Adjuvant TMZ in IDHm (median OS 12.5 years) · NO benefit w/TMZ for IDHwt

One error,double classifier endometrial can occur in 5 to 10% are sometimes offered treatment based on worse molecular while data suggests reverse MMRd–p53abn EC behaves like MMRd and POLEmut–p53abn EC behaves as POLEmut ⁦⁩ ⁦⁩ ⁦@ARRO_org⁩ pmc.ncbi.nlm.nih.gov/articles/PMC70…

We're hiring! Looking for a Director of MR Guided Radiation Therapy to join a growing team with a focus on trial development, programmatic growth, teaching. Apply here or feel free to reach out to me privately: careers.highmarkhealth.org/cancer-institu…

Confirms and establishes new SOC. First one comparing SRS to HAWBRT showing less symptom burden and better functional outcome with SRS @AndrewKellerMD @ARRO_org @ACROresident